Evidence map›Paper›PMID 40710195›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study.

Helen H Moon, Chiemeka Ike, Ruth W Dixon, Christopher L Crowe, Malvika Venkataraman, Valerie Morris, Mairead Kearney, Ivy Tonnu-Mihara, John Barron

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Helen H MoonKaiser Permanente Southern California, Riverside, CA 92505, USA.
Chiemeka IkeEMD Serono, Inc., Boston, MA 02210, USA.
Ruth W DixonCarelon Research, Wilmington, DE 19801, USA.
Christopher L CroweCarelon Research, Wilmington, DE 19801, USA.
Malvika VenkataramanCarelon Research, Wilmington, DE 19801, USA.
Valerie MorrisEMD Serono, Inc., Boston, MA 02210, USA.ORCID 0000-0002-0355-7379
Mairead KearneyMerck Healthcare KGaA, 64293 Darmstadt, Germany.
Ivy Tonnu-MiharaCarelon Research, Wilmington, DE 19801, USA.ORCID 0000-0002-8768-1990
John BarronCarelon Research, Wilmington, DE 19801, USA.

Funding

EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100004755) N/A
6 · The paper itself

Abstract

This retrospective cohort study evaluated characteristics, treatment patterns, and clinical outcomes in adults with locally advanced/metastatic urothelial carcinoma (la/mUC) receiving first-line (1L) systemic treatment with or without avelumab 1L maintenance (1LM) between January 2020 and July 2023. The index date was the first date with a claim for 1L systemic therapy after a la/mUC diagnosis. Patients with continuous health plan enrollment for ≥6 months before and ≥1 month after the index date were identified from Carelon Research's Healthcare Integrated Research Database. Of 2820 patients receiving 1L treatment, 37.0% received platinum-based chemotherapy (PBC); 39.0%, immuno-oncology (IO) monotherapy; and 24.0%, other therapies. Renal disease and other comorbidities influenced 1L regimen choice. Healthcare resource utilization (HCRU) and costs were reported for patients receiving second-line (2L) treatment. HCRU was high in 32.8% of patients (926 of 2820) who received 2L treatment. Median all-cause direct medical costs per patient per month were USD 15,859, USD 19,781, USD 11,346, and USD 9516 for 1L PBC, 1L PBC + avelumab 1LM, 1L IO monotherapy, and 1L other therapies, respectively. Most direct healthcare costs were attributed to all-cause outpatient visits.

Indexed as

Carcinoma, Transitional CellUrologic NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesTreatment OutcomeUnited Statesbladder cancerfirst-line treatmenthealthcare costsimmune checkpoint inhibitorsmetastatic urothelial carcinomaoutcome assessmentreal worldsystemic therapytreatment patterns

Identifiers

PMID40710195
PMCPMC12293318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.